

NEKTAR™**RECEIVED
CENTRAL FAX CENTER**

JAN 08 2008

201 INDUSTRIAL ROAD
SAN CARLOS, CA 94070-6256
650-631-3100 • 650-620-6395 FAX

FACSIMILE TRANSMITTAL SHEET

January 8, 2008

TO: Mail Stop Amendment
Commissioner for PatentsFROM: Mark A. Wilson
TELE. NO.: 650.620.5506

FAX NO.: (571) 273-8300

FAX NO.: 650.620.6395

RE: U.S. Serial No: 10/659,735
Attorney Docket No.: SHE0064.00TOTAL NO. OF PAGES INCLUDING COVER: 12

DOCUMENTS SUBMITTED:

- Transmittal Form (1 page)
- Fee Transmittal (1 page, in duplicate)
- Supplemental Information Disclosure Statement (4 pages)
- PTO/SB/08b (1 page)
- 1 Cited Reference (3 pages)

Certificate of Facsimile Transmission:I hereby certify that this correspondence is being facsimile transmitted
to the United States Patent and Trademark Office (USPTO), (571) 273-8300,on 1-8-2008 by Tina M. IngrandeSigned Tina M. Ingrande**NOTICE OF CONFIDENTIALITY**

This transmission is intended only for the use of the Addressee and may contain information that is:
1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the
intended recipient, you are hereby notified that any dissemination, distribution or copying of the
information contained in this facsimile is strictly unauthorized and prohibited. If you have received this
facsimile in error, please notify us immediately by collect phone to the sender named above.

JAN 08 2008

PTO/SB/21 (01-08)

Approved for use through 01/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/659,735
	Filing Date	September 9, 2003
	First Named Inventor	Antoni Kozlowski
	Art Unit	1618
	Examiner Name	Blessing M. FUBARA
Total Number of Pages in This Submission	Attorney Docket Number	SHE0064.00

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO/SB/08b; 1 cited reference
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Nektar Therapeutics	
Signature	<i>Mark A. Wilson</i>	
Printed name	Mark A. Wilson	
Date	January 8, 2008	Reg. No. 43,275

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature	<i>Tina M. Ingrande</i>		
Typed or printed name	Tina M. Ingrande	Date	01/08/2008

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JAN 08 2008

PTO/SB/17 (10-07)

Approved for use through 06/30/2010, OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).**FEE TRANSMITTAL
For FY 2008**☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	10/659,735
Filing Date	September 9, 2003
First Named Inventor	Antoni Kozlowski
Examiner Name	Blessing M. FUBARA
Art Unit	1618
Attorney Docket No.	SHE0064.00

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 50-0348 Deposit Account Name: Nektar Therapeutics

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	310	155	510	255	210	105	
Design	210	105	100	50	130	65	
Plant	210	105	310	155	160	80	
Reissue	310	155	510	255	620	310	
Provisional	210	105	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	210	105
Multiple dependent claims	370	185

Total Claims Extra Claims Fee (\$) **Fee Paid (\$)**

- 20 or HP = _____ x _____ = _____

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims Extra Claims Fee (\$) **Fee Paid (\$)**

- 3 or HP = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$260 (\$130 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 = _____ / 50 = _____ (round up to a whole number) x 260.00 = 0.00				

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Information Disclosure Statement - 1.17(p)

Fees Paid (\$)

180.00

SUBMITTED BY

Signature	<i>Mark A. Wilson</i>	Registration No. (Attorney/Agent)	43,275	Telephone	650-620-5506
Name (Print/Type)	Mark A. Wilson	Date	January 8, 2008		

This collection of information is required by 37 CFR 1.138. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JAN 08 2008

PATENT
Attorney Docket No.: SHE0064.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:)	
Antoni Kozlowski)	
)	Examiner: Blessing M. FUBARA
Application No.: 10/659,735)	Group Art Unit: 1618
Filed: September 9, 2003)	Confirmation No.: 3908
Title: METHOD FOR PREPARING)	
WATER-SOLUBLE POLYMER)	
DERIVATIVES BEARING A)	
TERMINAL CARBOXYLIC ACID)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56, §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

The reference listed in the attached Forms PTO/SB/08A and B may be material to examination of the above-identified patent application. Applicants submit this reference in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make this citation of official record in this application.

This Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this reference indeed constitutes prior art.

In compliance with 37 CFR §§1.98 (2) enclosed are copies of: (i) each foreign patent; (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office. The reference on the attached Form PTO/SB/08A and B identified by an asterisk (*) was previously cited by or submitted to the PTO in a prior application relied upon for an earlier filing date. Accordingly, in compliance with 37 CFR §§1.98 (d), copies of these references have not been provided.

PATENT

Attorney Docket No.: SHE0064.00

This Supplemental Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

☐ within three months of the filing date of a national application or an RCE; within three months of the date of entry of the national stage as set forth in section 1.491 in an international application; or before the mailing date of a first Office action on the merits (whichever event occurs last);

☒ more than three months from the filing date of an application and after the mailing date of a first Office action on the merits, but before the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311 (whichever occurs first), and is accompanied by:

☒ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00); or

☐ one of the following statements as specified in 37 CFR 1.97(e) that:

☐ each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the supplemental information disclosure statement; or

☐ no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement; or

☐ after the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311, but on or before the payment of the issue fee, and is accompanied by each of:

☐ the following petition:

PATENT

Attorney Docket No.: SHE0064.00

Applicant hereby requests consideration of the accompanying information disclosure statement;

☐

the petition fee set forth in 37 CFR 1.17(i) (\$130.00); and

☐

one of the following statements as specified in 37 CFR 1.97(e) that:

☐

each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐

no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement.

☐

Each item of information contained within this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 1.56(c) more than thirty days prior to the filing of the Supplemental Information Disclosure Statement. Accordingly, this Information Disclosure Statement does not constitute a failure on the part of the Applicant to engage in reasonable efforts to conclude prosecution of the application as set forth in 37 CFR 1.704 "Reduction of period of adjustment of patent term."

JAN 08 2008

PATENT
Attorney Docket No.: SHE0064.00☐ Attached is Check No. _ in the amount of \$0.☒ Please charge the amount of \$180.00 to Deposit Account 50-0348.☒ If it is determined that any additional fees are due, the Commissioner is hereby authorized and requested to charge such fees to Deposit Account 50-0348.Respectfully submitted on behalf of,
Nektar Therapeutics AL, Corporation,Dated: January 8, 2008

By:

M. A. Wilson
Mark A. Wilson
Reg. No. 43,275**CORRESPONDENCE ADDRESS:**Nektar Therapeutics
201 Industrial Road
San Carlos, CA 94070
(650) 631-3100 (Telephone)
(650) 620-6395 (Facsimile)01/09/2008 VBUI11 00000043 500348 10659735
01 FC:1006 100.00 DA